Free Trial

Cardinal Health (CAH) Stock Forecast & Price Target

$95.55
+0.13 (+0.14%)
(As of 01:02 PM ET)

Cardinal Health - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 13 Wall Street analysts who have issued ratings for Cardinal Health in the last 12 months, the stock has a consensus rating of "Hold." Out of the 13 analysts, 1 has given a sell rating, 5 have given a hold rating, and 7 have given a buy rating for CAH.

Consensus Price Target

$109.67
14.77% Upside
High Forecast$130.00
Average Forecast$109.67
Low Forecast$90.00

According to the 13 analysts' twelve-month price targets for Cardinal Health, the average price target is $109.67. The highest price target for CAH is $130.00, while the lowest price target for CAH is $90.00. The average price target represents a forecasted upside of 14.77% from the current price of $95.55.

TypeCurrent Forecast
7/24/23 to 7/23/24
1 Month Ago
6/24/23 to 6/23/24
3 Months Ago
4/25/23 to 4/24/24
1 Year Ago
7/24/22 to 7/24/23
Consensus Rating
Hold
Moderate Buy
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
3 Buy rating(s)
Hold
5 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
8 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$109.67$109.67$103.07$90.00
Forecasted Upside14.77% Upside10.83% Upside7.01% Upside13.01% Upside
Get Cardinal Health Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CAH and its competitors with MarketBeat's FREE daily newsletter.

CAH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CAH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cardinal Health Stock vs. The Competition

TypeCardinal HealthMedical CompaniesS&P 500
Consensus Rating Score
2.46
2.72
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside14.93% Upside3,033.60% Upside9.26% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/19/2024Citigroup
3 of 5 stars
 Lower TargetNeutral ➝ Neutral$115.00 ➝ $107.00+11.98%
7/9/2024Evercore ISI
2 of 5 stars
 Lower TargetIn-Line ➝ In-Line$115.00 ➝ $105.00+9.09%
7/9/2024Robert W. Baird
2 of 5 stars
 Boost TargetOutperform ➝ Outperform$129.00 ➝ $130.00+34.19%
5/15/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$120.00 ➝ $115.00+17.67%
4/29/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight ➝ Underweight$96.00 ➝ $94.00-8.54%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/26/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$125.00+15.64%
2/5/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$122.00 ➝ $125.00+21.17%
1/3/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$117.00+14.01%
11/17/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$101.00 ➝ $112.00+8.24%
8/16/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$88.00 ➝ $90.00-0.56%
8/16/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$92.00 ➝ $100.00+10.46%
8/16/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$94.00 ➝ $96.00+6.04%
7/17/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$91.00 ➝ $99.00+6.29%
6/12/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$90.00 ➝ $100.00+15.82%
5/8/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$88.00 ➝ $90.00+8.59%
11/4/2022Bank Of America (Bofa)
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Neutral$64.00 ➝ $80.00+2.97%
8/16/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$59.00 ➝ $72.00+2.90%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:22 PM ET.

CAH Forecast - Frequently Asked Questions

What is Cardinal Health's forecast for 2024?

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Cardinal Health is $109.67, with a high forecast of $130.00 and a low forecast of $90.00.

Should I buy or sell Cardinal Health stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardinal Health in the last twelve months. There is currently 1 sell rating, 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CAH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CAH, but not buy additional shares or sell existing shares.

Does Cardinal Health's stock price have much upside?

According to analysts, Cardinal Health's stock has a predicted upside of 11.71% based on their 12-month stock forecasts.

What analysts cover Cardinal Health?

Cardinal Health has been rated by research analysts at Argus, Citigroup, Evercore ISI, Robert W. Baird, and Wells Fargo & Company in the past 90 days.

Do Wall Street analysts like Cardinal Health more than its competitors?

Analysts like Cardinal Health less than other "medical" companies. The consensus rating for Cardinal Health is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CAH compares to other companies.


This page (NYSE:CAH) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners